Publication Name	World Journal of Hepatology
Manuscript ID	33929
Country	Australia

Received	2017-03-15 09:43
Peer-Review Started	2017-03-15 15:49
To Make the First Decision	2017-04-14 10:35
Return for Revision	2017-04-20 10:10
Revised	2017-04-30 11:25
Second Decision	2017-05-10 14:40
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-05-19 04:07
Articles in Press	2017-05-19 04:07
Publication Fee Transferred	2017-05-29 06:59
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-06-30 10:03
Publish the Manuscript Online	2017-07-05 04:40

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc.All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome
Manuscript Source	Unsolicited Manuscript
All Author List	Angus W Jeffrey, Yi Huang, W Bastiaan de Boer, Leon A Adams, Gerry MacQuillan, David Speers, John Joseph and Gary P Jeffrey
Funding Agency and Grant Number
Corresponding Author	Dr. Angus W Jeffrey, School of Medicine, University of Notre Dame, 32 Mouat St, Fremantle, WA, 6160, Australia. angus.jeffrey1@my.nd.edu.au
Key Words	Chronic; Prognosis; Direct acting antivirals; Serum; Hepatitis C
Core Tip	The growing burden of hepatitis C is well recognized. The use of serum fibrosis markers such as Hepascore to monitor change in clinical risk in hepatitis C has a significant potential benefit to optimise the management in these patients. However, there is no information on the value of serial serum fibrosis tests and their improvement over time in determining changes in liver related clinical outcomes. We have found that there is a decreased risk of mortality and morbidity in chronic hepatitis C patients when the patient has an improving delta Hepascore, and serial tests may be of use in clinical practice.
Publish Date	2017-07-05 04:40
Citation	Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856
URL	http://www.wjgnet.com/1948-5182/full/v9/i19/850.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i19.850

Full Article (PDF)	WJH-9-850.pdf
Full Article (Word)	WJH-9-850.doc
Manuscript File	33929-Review.docx
Answering Reviewers	33929-Answering reviewers.pdf
Audio Core Tip	33929-Audio core tip.mp3
Biostatistics Review Certificate	33929-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	33929-Conflict-of-interest statement.pdf
Copyright License Agreement	33929-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	33929-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	33929-Institutional review board statement.pdf
Peer-review Report	33929-Peer-review(s).pdf
Scientific Misconduct Check	33929-Scientific misconduct check.pdf
Scientific Editor Work List	33929-Scientific editor work list.pdf